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Abstract 
 
An episode of acute severe ulcerative colitis (UC) represents an important watershed 
moment during the course of the disease with a heightened risk of colectomy during and 
following these episodes. As such, the prompt identification and early implementation of 
the appropriate treatment is paramount to obtaining the best clinical outcomes for these 
unwell patients.  
 
A prospective database of 349 consecutive presentations of Truelove and Witts criteria 
qualifying moderate and severe UC was collated at a single referral centre.  
 
This resource was interrogated to identify the C-reactive protein (CRP) level that 
corresponds with the erythrocyte sedimentation rate (ESR) that is widely accepted as a 
marker of severe disease activity. A CRP threshold of  ≥12mg/L was found to be an 
inclusive and sensitive cut off that when incorporated into the Truelove and Witts criteria, 
replacing the traditional ESR >30mm/h criterion, had similar performance characteristics 
when applied to the assessment of UC disease activity.    
 
On the level of the individual patient, the serial CRP concentration is one of the few 
informative and objective measures of disease acuity and treatment response that will alter 
management during the hospital admission. This study provides the previously lacking 
reassurance that baseline immunomodulator usage status need not be taken into account 
when interpreting the ESR or CRP levels on presentation in established UC patients not 
on biologic therapy. 
 
As many published IBD severity and prognostic indices in contemporary use incorporate 
either the ESR or CRP as objective markers of disease acuity, this study has high 
translatability to patients with a secure diagnosis of UC not in their initial flare.  
 
Seventeen clinical, laboratory and endoscopic variables present at the time of hospital 
presentation were assessed for their ability to differentiate intravenous corticosteroid 
therapy responders from non-responders. 
  
A risk score based on a logistic model including the admission indices of oral corticosteroid 
failure, bowel frequency, CRP, albumin and either disease duration or Mayo endoscopic 
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subscore (MES) was trained on a set of 349 presentations of acute UC. This individualised 
risk score has the potential to inform clinicians as to the timing of treatment escalation in 
acute UC. 
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Chapter 1 
 
The evaluation of C-reactive protein as a marker of disease severity in acute severe ulcerative colitis 
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1.1 Literature review 
 
Introduction 
An episode of acute severe ulcerative colitis (UC) complicates the disease course of a quarter of all 
patients with this diagnosis.1 These exacerbations of disease activity represent an important 
watershed moment during the course of the disease. Studies with long follow up periods have 
shown that the risk of colectomy is elevated for 18 months to two years following an acute 
episode.2, 3 While this risk is modulated by many parameters, a key variable that was identified as 
early as 1955 is that of disease activity and systemic toxicity at the time of treatment initiation.4 A 
snapshot of disease activity at this juncture also carries with it significant prognostic power over the 
more immediate clinical outcomes at the time of discharge.1 Therefore, the early and accurate 
identification of severe UC is imperative for timely commencement of the appropriate treatment to 
minimise the risk of colectomy in both the short and long term. 
 
The Truelove and Witts criteria for ulcerative colitis. 
There are a range of disease severity indices that are currently in use in both clinical and research 
settings.5, 6 The original Truelove and Witts criteria (TWC) disease activity index was used for the 
final report on one of the first randomised controlled trials in the then nascent field of 
gastroenterology.4 Its subject was the comparison of the effect of intravenous corticosteroids with 
placebo in the setting of mild-severe UC exacerbations.  
 
In addition to the mandatory criteria of six or more bloody liquid stools within 24 hours there is a 
requirement for at least one of: tachycardia (heart rate >90beats per minute), fever (temperature 
>37.8°C), anaemia (haemoglobin <75% of the normal range, taken at 105 mg/L) or systemic 
inflammation (erythrocyte sedimentation rate (ESR) of >30mm/h). Mild disease episodes are 
assessed as ≤4 stools per day without any of the above additional criteria. Moderately severe cases 
are those that fall between mild and severe criteria. There is no mention in this publication or any 
supplementary material that indicate how these indices were derived or validated in a validation 
cohort. Indeed, the original authors used clinical experience to guide selection of the criteria and 
their binary cut off thresholds. 
 
Despite this the TWC has a number of strengths that have contributed to its longevity. The variables 
in this index are all objective except for the reliance on patient reporting of stool frequency and 
blood content in the 24 hours preceding presentation. The special investigations are affordable, 
routinely performed and well within the repertoire of most accredited laboratories. Limitations of 
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the criteria include the fact that the TWC allocates patients into severity categories in a non-linear 
fashion using cut off values. For instance a stool frequency of six or 20 bloody stools per day are 
effectively given the same weight.  
 
Additionally, ESR has been supplanted by the C-reactive protein (CRP) as the marker of choice for 
the assessment of acute systemic inflammation. When the ESR is not assessed soon after 
presentation the criteria are incomplete and can be difficult to apply in circumstances when no other 
criteria in addition to the mandatory stool frequency criteria are fulfilled. This situation contributes 
to the difficulty in assessing these patients via telephone when they are referred for consideration of 
transfer from secondary referring hospitals.   
 
Erythrocyte sedimentation rate 
This test was developed in 1897 and is the measurement of the vertical descent of erythrocytes in a 
column of plasma over one hour. The result of the test reflects the balance between 
prosedimentation factors including those promoting rouleaux formation and anti-sedimentation 
factors. The zeta potential is the term for the electrostatic force repelling erythrocytes from each 
other. This is due to negatively charged sialic acid residues present on the erythrocyte membrane. In 
the setting of inflammation, the increase in fibrinogen and gamma globulins in the plasma reduces 
the zeta potential contributing to increased rouleaux formation.  
 
Due to its very nature the ESR is affected by many parameters (Table 1.1). In patients presenting 
with severe UC the most important are anaemia, which is often microcytic, and a low plasma 
protein concentration.  ESR is inversely proportional to haematocrit and is an exponential function 
of the plasma colloid concentration.7 
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Table 1.1 Factors known to influence ESR  
Factors that increase ESR Factors that decrease ESR 
Anaemia Microcytosis 
Inflammation Hypoproteinaemia 
Female gender Spherocytosis or acanthocytosis 
Increasing age Polycythemia 
Macrocytosis Hypofibrinogenaemia 
Pregnancy Hypogammaglobulinaemia 
Malignancy Vibration during testing 
Tilted tube Clotted sample or inadequate mixing 
Adapted from: https://www.slideshare.net/RaviJain7/esr-9713905 
 
C-reactive protein 
First characterised in the early 1930s, CRP was found to react with the somatic C-antigen of 
Streptococcus pneumoniae.8 Initially thought to be pathogenic, this annular, pentameric protein was 
later proven to be natively synthesised in the liver. It is released in response to proinflammatory 
cytokines including IL-6, IL-1β and TNFα released from macrophages and T-cells as part of the 
acute phase response. It plays an important part of the innate immune system by binding to 
phosphocholine on the surface of microorganisms and inducing activation of the classical 
complement pathway. 
 
As UC is primarily a disease of the colonic mucosa, active disease results in relatively lower 
production of acute phase cytokines compared to those seen in the transmural inflammation 
characteristic of active Crohn’s disease (CD).9 This can commonly result in the return of CRP tests 
within the normal range in the setting of clinically active UC.  
 
For a diagnosis of acute severe UC the ECCO guidelines indicate that the ESR or CRP are 
equivalent at a cut off value of >30mm/h or >30mg/L respectively to qualify as an additional 
TWC.10 The UK IBD audit used the hurdle of a CRP >10mg/L for qualifying for acute severe UC.11 
Neither of these cut offs have been presented with data detailing their derivation. 
 
Comparison of inflammatory markers in ulcerative colitis 
The most thorough and contemporaneous study in ulcerative colitis patients was performed in the 
paediatric setting by Turner et al.12 These investigators used retrospective data to determine levels 
of ESR and CRP corresponding to clinical activity, defined as remission, mild, moderate and severe 
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disease, by comparing them to the previously validated paediatric UC activity index (PUCAI) score, 
endoscopic activity and other indices of UC activity (Figure 1.1). Despite the lack of a direct 
comparison between the ESR and CRP values, this study was informative.  
 
 
 
 
 
 Figure 1. ESR and CRP compared to disease activity by PUCAI score12 
Table 2. Spearman’s correlation of blood indices with constructs of UC disease activity12 
 
Figure 1.1 ESR and CRP compared to disease activity by PUCAI score12 
 
 
 
 
 
Figure 1.1 ESR and CRP compared to disease activity by PUCAI score12 
 
Overall CRP was found to have a slightly higher AUROC and mean Spearman’s correlation 
coefficient than ESR when it was compared to a number of activity indices (Table 1.2). CRP was 
also found to be better at discriminating severe from moderate disease with a threshold of >9mg/L 
for severe disease compared to an ESR of >37mm/h. At the other end of the disease activity 
spectrum ESR was found to have more discriminating power between remission and mild disease 
than CRP. These results contrast findings in Crohn’s disease where CRP is markedly superior as a 
marker of disease activity.13, 14 
 
In the longitudinal component of this study, when one of ESR or CRP were found to be associated 
with disease activity, serial measurement of the disease activity-associated test in isolation was able 
to accurately reflect disease activity in 85% of subsequent encounters. Higher readings of both ESR 
and CRP were found in extensive (Montreal classification E3) versus left-sided disease (Montreal 
classification E1-E2). 
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Table 1.2 Spearman’s correlation of blood indices with constructs of UC disease activity12 
 
 
In a 1982 study of 50 patients at Hammersmith Hospital, London nine patients were considered to 
have severe disease as per the Truelove and Witts criteria. Only 4/9 were admitted indicating either 
a high admission threshold or that some moderately severe cases were present in the series. In these 
severe patients the CRP median was 12mg/L (range, 2-33). ESR median 28mm/h (range, 10-59). A 
smaller study performed in India found that a CRP of ≥12mg/L was found in 14/17 patients with 
severe UC.  
 
ESR and CRP were both reported in a retrospective study of 67 severe UC patients in Italy.15 ESR 
and CRP levels at study entry were similar between the two groups separated by response (52 ± 
29mm/h, 48.3 ± 47.5mg/L) or non-response to intravenous steroid therapy (80 ± 32mm/h,  97.3 ± 
110mg/L), respectively.  
 
There were no direct comparative analyses between ESR and CRP results in any of these early 
series. 
 
Inflammatory markers in Crohn’s disease 
Early work by Tromm et al evaluated several inflammatory markers including ESR and CRP and 
correlated their levels with endoscopic appearance separating the participants on the basis of mild or 
severe ulceration.16 With hindsight, the high rate of 37% of both groups having disease limited to 
the large bowel indicates a likely admixture of CD and UC. Unsurprisingly, higher readings of both 
inflammatory markers were found in the severe versus the mild ulceration and control groups. In a 
direct comparison between ESR and CRP the correlation coefficient was r=0.29. When the 
inflammatory markers were compared to the Crohn’s disease activity index (CDAI) the coefficients 
were r=0.24 and r=0.37 respectively for ESR and CRP. 
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A randomised controlled trial of mesalazine for the prevention of CD flares following a course of 
oral corticosteroids generated data that enabled the investigators to construct a simple risk 
prediction model for CD flares occurring in the six week period following the collection of serially 
collected inflammatory markers.17 The median CRP at the commencement of the study was 
relatively high at 15.2mg/L, ESR 18mm/h. This median CRP level is consistent with a degree of 
persistent disease activity at enrolment.  
 
Of the 71 enrolled patients, 38 had a relapse during the 54 week study period. The biological 
prediction score was defined as either CRP >20mg/L and/or ESR >15mm/h. A positive prediction 
score conferred an eight times relative risk of CD flare compared to those patients with a negative 
risk score. A strength of this score is its negative predictive value of 97%. Unlike the previous study 
there was no direct comparison made between ESR and CRP.  
 
ESR and CRP in other inflammatory diseases 
In a study of over 700 rheumatoid arthritis patients the ESR and CRP were compared directly to an 
accepted index of disease activity.18 As in most IBD studies there was no direct comparison 
between ESR and CRP. 
 
CRP was found to be only slightly better as a measurement of inflammation while ESR, because it 
is affected by non-acute phase factors such as immunoglobulins and rheumatoid factor, may be a 
better measure of general disease severity. 
 
In summary, there is a high degree of clinical relevance to the accurate and prompt identification of 
acute severe episodes of UC. ESR and CRP are both useful inflammatory markers that can assist in 
this differentiation. Key knowledge gaps include an evidence-based CRP cut off for the diagnosis of 
severe UC in adults to guide patient disposition and acute management. 
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1.2 Aims 
 
 To determine the concentration of CRP corresponding to an ESR>30mm/h in adult patients 
presenting with acute severe colitis as defined by the Truelove and Witts criteria. 
 
 To compare clinical outcomes between groups stratified for disease severity on the basis of 
number of Truelove and Witts criteria satisfied at presentation using either ESR or a newly 
derived CRP criterion. 
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1.3 Hypothesis 
 
The equivalent CRP cut-off to an ESR of 30mm/h in severe UC will be between the already 
proposed CRP cut offs of >10mg/L and >30mg/L. 
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1.4 Methods 
  
Patients 
Individuals who presented to a single tertiary centre with acute severe UC by TWC during the study 
period were eligible for study inclusion. Initial presentations of UC were included as were those 
generated by known UC patients. The diagnosis of UC was confirmed by histology together with 
endoscopic, radiological and clinical correlation. Patients were required to have had a paired ESR 
and CRP result from within 24 hours of presentation to be included. Written informed consent was 
obtained from all patients included in this study and the study protocol approved by the Royal 
Brisbane and Women’s Hospital medical ethics committee. 
 
Patients on immunomodulators, oral corticosteroid and/or 5-aminosalicylates at the time of 
admission were included in the study.  Patients were considered to be taking an immunomoudulator 
if they had been on a thiopurine for four months or more prior to presentation. Treatment adherence 
was monitored with thiopurine metabolite levels when these became available For the purpose of 
maintaining consistency across the cohort, those patients on any biologic therapy at the time of 
admission were excluded.  
 
Laboratory tests 
ESR tests were performed on the Ves-matic Junior 20 (Diesse Diagnostica Senese, Monteriggioni, 
Italy). CRP was assessed on the Roche-Hitachi 747 Analyzer (Roche Diagnostics, Mannheim, 
Germany, 1996-2008) and the Beckman-Coulter DxC 800 Analyzer, (Beckman-Coulter, Fullerton, 
USA, 2008-2017) platforms. 
 
Statistics 
R version 3.4.0 “You Stupid Darkness” (R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria) was used for all analyses. 
 
Each unique CRP level reported in the dataset was tested as a potential cut-off point to approximate 
an ESR of >30mm/h. For each tested cut-off, a confusion matrix was generated between ESR 
>30mm/h and the CRP cut-off. The positive predictive value (PPV) was then used to establish the 
lowest CRP cut off with a PPV >85%.  
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Chi-squared and Fisher’s exact tests were used to compare corticosteroid therapy failure and 
colectomy rates between ESR>30 and CRP≥12 allocated groups. 
 
Mann-Whitney U-tests were used to compare presentation faecal calprotectin and Mayo endoscopic 
subscores (MES) between groups separated by the inflammatory marker criteria used and stratified 
by the number of TWC satisfied at presentation.  
 
See the Statistics subheading of the Methods section in Appendix A for a full description of the 
statistical methods undertaken in an attempt to obtain an expression that would accurately predict an 
ESR result based on the CRP adjusted for clinical variables available at the time of presentation. 
This analysis was performed in a larger (n=270) and more heterogeneous patient series.   
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1.5 Results 
 
During the study period 349 presentations of moderate-severe UC were recorded. Of these, 204 
presentations were considered to be severe by TWC and initially presented directly to the Royal 
Brisbane and Women’s Hospital. Of these presentations, 163/204 had paired ESR and CRP levels 
recorded within 24 hours presentation (Table 1.3). These presentations were generated by 153 
individuals. There were 41 patients who presented to the Royal Brisbane and Women’s Hospital 
with severe UC who did not have an ESR recorded within the first 24 hours of admission (ESR 
negative group). There were no deaths of hospitalised patients as a consequence of UC, surgery or 
any subsequent complications.   
 
 
Table 1.3. Acute severe UC patient characteristics on admission 
 Study participants 
(n=163) 
ESR negative group 
(n=41) 
p-value 
Gender (male) 85 (52%) 19 (46%) 0.51 
Age at admission in years median (IQR) 33 (25-43) 35 (25-53) 0.45 
Disease duration in years median (IQR) 2 (1.2-9.2) 1.5 (0-4) 0.004 
First UC presentation 
Relapse 
23 (14%) 
140 (86%) 
15 (37%) 
26 (63%) 
0.00095 
Disease extent (Montreal classification) 
Proctitis (E1)        
Left-sided (E2)    
Extensive (E3)      
  
2 (1%) 
55 (34%) 
106 (65%) 
 
0 (0%) 
19 (46%) 
22 (54%) 
0.85* 
Immunomodulator on admission 
No                 
Yes  
   
123 (75%) 
40 (25%) 
 
27 (66%) 
14 (34%) 
0.21 
Bowel frequency median (IQR) 10 (8-15) 10 (7-11) 0.081 
CRP mg/L median (IQR) 58 (28-109) 60 (24-140) 0.74 
Albumin g/L mean (Standard deviation) 32 (6) 30 (6) 0.14 
 
UC: ulcerative colitis; TWC: Truelove and Witts criteria; CRP: C-reactive protein; IQR: 
interquartile range. *E1 and E2 disease was pooled for this analysis. 
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There was a higher rate of first presentations of UC in the ESR negative cohort (37%) compared to 
those with ESR recorded (14%; p=0.00095). This result contributed to the reduced UC disease 
duration prior to the severe UC episode in this cohort (median 1.5 versus 2 years, p=0.004).  
 
In the paired ESR and CRP group there was a male predominance of 52% with a median age of 33 
years at admission. Fourteen percent of cases were index (first) presentations of UC. The median 
time elapsed between UC diagnosis and admission was two years (range 0-45 years). Two thirds 
(65%) of cases had disease proximal to the splenic flexure. One quarter (25%) of cases were 
receiving systemic immunosuppression at the time of presentation.  
 
Determining and applying the CRP cut off for the Royal Brisbane and Women’s Hospital severe 
colitis n=163 cohort 
Compared to the traditional ESR cut off of >30mm/h, the lowest CRP value that produces a PPV of 
85% was ≥12mg/L. This threshold captures 95% of cases with an ESR >30mm/h. The area under 
the curve is 0.82. A cut off of 31mg/L generated a PPV of 87% (Table 1.5); this captured 81% of 
cases. The PPV is consistently above 80% for CRP cut off values from 20-200mg/L (Figure 1.2). 
The level of accuracy decreased markedly above a cut off of ≥12mg/L (Figure 1.3).   
 
Table 1.4 CRP cut off positive predictive values for a paired ESR of >30mm/h 
CRP cut off 
(≥mg/L) 
PPV (%) NPV (%) Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
12 85 63 95 35 82 
18 86 50 88 44 79 
25 86 44 84 47 77 
31 87 43 81 56 75 
CRP: C-reactive protein; PPV: positive predictive value for CRP cut off having a paired ESR 
>30mm/h; NPV: negative predictive value for CRP cut off having a paired ESR >30mm/h  
 
27 
 
  
Figure 1.2 Positive predictive value for a matched ESR >30mm/h for a paired CRP cut off 
28 
 
 
The application of the new CRP≥12mg/L cut off to the data altered the total number of TWC 
fulfilled for 29/163 (18%) of patients (Figure 1.3). Conversely, 134 or 82% of presentations 
remained unchanged in their number of TWC satisfied on admission. The maximum total number 
of TWC fulfilled was five. This was assessed as a combination of the single mandatory stool 
frequency criteria with up to four additional criteria. 
 
 Figure 1.3 CRP accuracy at varying CRP cut off values.  
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Figure 1.4 Number of Truelove and Witts criteria present at admission by ESR and CRP criteria. 
The four patients downgraded from TWC severe to moderate colitis when the CRP≥12mg/L 
criterion was applied in place of the ESR>30mm/h criterion only fulfil the bowel frequency 
criterion of the TWC and are represented by the green bar at the x-axis value of 1. 
 
Twenty-two patients increased their total number of fulfilled TWC by one. Conversely seven 
patients had a decrease of total TWC by one. Overall, there was a net increase in the number of 
TWC satisfied in 15 (9%) patients when the CRP≥12mg/L criteria was applied. Four patients were 
downgraded from severe to moderate colitis. One of these patients underwent colectomy prior to 
discharge.  
 
Clinical outcomes 
Following the application of the CRP≥12mg/L cut off there were no statistically significant changes 
to the rate of corticosteroid therapy failure in any single group separated by the number of TWC 
met at admission (TWC 2/5, 3/5 or ≥4/5). Those patients who satisfied 4 or 5 TWC on presentation 
were combined to provide sufficient numbers for a meaningful analysis (Figure 1.5). When the 
different inflammatory marker systems were compared the p-values for the corticosteroid failure 
rate between TWC categories 2/5, 3/5 and ≥4/5 combined were 1, 0.71 and 0.88, respectively. 
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There were no statistically significant differences by Chi-squared test in the colectomy-by-
discharge rate by number of TWC satisfied on admission between the ESR>30 and CRP≥12 criteria 
(Figure 1.6). TWC categories 4 and 5 were combined to provide sufficient numbers for the analysis. 
The p-values for TWC categories 2, 3 and ≥4/5 were 1, 1 and 0.96, respectively. 
 
 
Figure 1.5 Corticosteroid failure rate by number of TWC and inflammatory marker allocation 
system 
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Figure 1.6 Colectomy-by-discharge rate by number of TWC fulfilled at admission and 
inflammatory marker allocation system 
 
 
Other markers of disease severity on admission to hospital 
 
Faecal calprotectin 
Faecal calprotectin results were available for 57 patients with ESR criteria and the 55 patients with 
CRP criteria qualifying severe colitis (Figure 1.7). The median calprotectin in the TWC 2/5 group 
was 1750μg/g (n=22, IQR 870-4325μg/g) and 2550μg/g (n=16, IQR 1135-4400μg/g) for ESR>30 
and CRP≥12 criteria, respectively. The median calprotectin in the TWC 3/5 group was 1800μg/g 
(n=21, IQR 530-3900μg/g) and 1600μg/g (n=25, IQR 530-4600μg/g) for ESR>30 and CRP≥12 
criteria, respectively. The median calprotectin in the TWC ≥4/5 group was 2700μg/g (n=14, IQR 
1475-3950μg/g) and 2700μg/g (n=14, IQR 1475-3950μg/g) for ESR>30 and CRP≥12 criteria, 
respectively.  
 
There were no statistically significant differences between ESR>30 and CRP≥12 allocated groups 
by TWC satisfied at admission. The p-values were 0.68, 0.86 and 0.72 for TWC 2/5, TWC 3/5 and 
TWC ≥4/5, respectively. 
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Figure 1.7 Faecal calprotectin at presentation by TWC activity on presentation and inflammatory 
marker allocation system. (ESR>30 n=57, CRP≥12 n=55; four data points not visualised due to y-
axis limitation of 8000μg/g). 
 
Mayo endoscopic subscore 
Mayo endoscopic subscore results were available for 118 TWC severe UC patients by ESR>30 
criteria (n=2, 8, 53, 55 for MES 0-3, respectively) and 114 with TWC severe UC patients by 
CRP≥12 criteria (n=2, 8, 51, 53 for MES 0-3, respectively; Figure 1.8). Grouped by the number of 
TWC present at admission there were n=TWC 2/5: 56, 39; TWC 3/5: 37, 49; TWC ≥4/5: 25, 26; by 
ESR>30 and CRP≥12 criteria, respectively.  
 
There were no statistically significant differences between ESR>30 and CRP≥12 allocated groups 
by TWC satisfied at admission. (TWC ≥4/5 groups combined for this analysis). The p-values were 
0.57, 0.70 and 0.66 for TWC 2/5, TWC 3/5 and TWC ≥4/5, respectively. 
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Figure 1.8 Mayo endoscopic subscore at presentation by TWC fulfilled and inflammatory marker 
allocation system 
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1.6 Discussion 
 
The primary finding of this observational study is the establishment of an evidence-based CRP 
equivalent to the previously used ESR>30mm/h cut off proposed by Truelove and Witts in 1955 to 
be used as an additional criterion for the classification of UC disease severity. This derivation was 
performed in a real-world data set of 163 presentations of severe UC as assessed according to the 
historical TWC. As encountered in clinical practice, there was a wide spectrum of both UC disease 
activity and systemic toxicity observed in the presenting patients.  
 
The proposed CRP cut off of ≥12mg/L is an inclusive and conservative additional Truelove and 
Witts criterion capturing 95% of patients with a paired ESR of >30mm/h. When compared to the 
ESR-based criterion it resulted in a net increase in the number of TWC satisfied in 9% of 
presentations. 
 
When the important clinical outcomes of corticosteroid therapy failure and inpatient colectomy 
were considered, no statistical differences were observed between the ESR>30 and CRP≥12 
allocated groups. From this result it can be inferred that the 18% of patients that underwent a 
change in their TWC allocation underwent a balanced redistribution along the TWC severity 
continuum producing a distribution of patients with clinical characteristics analogous to those 
produced by the traditional ESR criterion. 
 
The fact that one patient who was reclassified from severe to moderate UC underwent inpatient 
colectomy is of interest but is not an unexpected outcome, nor is it an outcome reaching statistical 
significance. Operative management and the initiation of biologic therapy are not uncommon 
clinical outcomes in this clinically important but frequently overlooked group with TWC moderate 
disease who have accumulated a significant inflammatory burden. There is a paucity of data 
specifically relating to the moderate severity group because many studies of acute UC requiring 
hospital admission combine patients with moderate and severe levels of disease activity.19-22  
 
The new CRP-based criterion did not produce any statistically significant differences in the absolute 
number of patients with either corticosteroid therapy failure or the closely related clinical outcome 
of rescue therapy administration in moderate and severe groups.  
 
Consistency between the ESR>30 and CRP≥12 allocated groups is evidenced by the lack of 
statistically significant differences observed in validated markers of disease activity. These included 
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the presenting faecal calprotectin and the Mayo endoscopic subscore as assessed in 57 and 118 
patients, respectively. 
 
The group of 163 presentations are representative of the 204 presentations to the main study site 
during the period under evaluation. The statistically significant differences between the ESR 
negative (n=41) and main cohort (n=163) were limited to a higher rate of first presentations of UC 
and reduced disease duration in the former group. Key objective clinical parameters known to affect 
clinical outcomes in severe UC including bowel frequency, albumin, CRP and immunomodulator 
usage status were not found to be statistically disparate between these groups. 
 
The establishment of a CRP cut off is of clinical importance given the relative accessibility of this 
test in contemporary clinical practice, the ongoing applicability of the TWC in clinical decision 
making, and the importance of the inflammatory marker criterion within this instrument. Of the 163 
severe cases as per the original TWC, 129 (79%) had an ESR >30mm/h. For 47 (29%) of these 
cases an ESR of >30mm/h is the only additional Truelove and Witts criterion admitting them into 
the severe category. 
 
Reluctance in utilising the TWC is borne of a number of previously described limitations including 
its unclear statistical origins, lack of successful validation and the abundance of other 
contemporaneous instruments.5, 6 Despite these detractions Dinesen et al have shown that the TWC 
not only provides a tool for disease activity categorisation, but that together they also have 
prognostic value with regards to predicting the likelihood of inpatient colectomy.1  
 
The comparison of our data with the Turner et al. study yields low validity. This paediatric series, 
while having a significant number of patients admitted for intravenous steroids (227/451), assessed 
disease activity after three days of intravenous corticosteroid therapy to obtain a more 
heterogeneous pool of results.12 Additionally, disease activity was determined by a very different 
instrument that contains a paucity of objective measures of disease activity. Finally, baseline CRP 
values are likely to be higher with increasing age and body mass index encountered in adult 
series.23, 24 This latter point was a key reason why the less specific CRP cut off of ≥10mg/L was not 
chosen. 
 
The described CRP cut off of ≥12mg/L lies between the previously described cut offs of >10mg/L 
and >30mg/L reported in the UK IBD Audit and the ECCO e-guidelines, respectively.10, 11  
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In the 2004 study by Ho et al describing a score predicting failure of rescue therapy from day 0-3 
data from a Scottish cohort of 167 TWC severe UC cases the mean ESR and median CRP were 44.8 
(standard deviation 26.5) and 4.4 (IQR 2.1–13.3), respectively.25 Whilst there was no comparison 
between the ESR and CRP reported, the CRP IQR values reflect the fact that the majority of these 
severe UC cases have only a mild elevation of CRP with some in the normal range. This finding is 
supported by the data presented in this chapter.       
 
The PPV threshold of >85% was chosen to reflect the level of assurance most clinicians would 
accept for the CRP cut off to produce a similar disease activity grading to the traditional ESR-based 
criterion. This level of prediction is identical to the 85% risk of inpatient colectomy conferred by 
satisfying the Day 3 (Oxford) criteria for assessment of corticosteroid-refractory disease, a widely 
accepted indication for treatment escalation or surgery in this context.26 The selected CRP cut off 
also generated the highest combined accuracy and PPV of all CRP values on presentation. 
 
Some investigators have proposed using either or both of ESR and CRP in the assessment of acute 
IBD.17 As the purpose of this study was to supersede the ESR assay in favour of the CRP, this 
approach was not taken.  
 
For the purposes of this study we have kept within the framework of the original Truelove and 
Witts disease activity assessment criteria. The rate of colectomy-by-discharge plateaued after three 
TWC were satisfied. This suggests that the weighting of each of the additional TWC with regards to 
the degree of risk of colectomy they confer is likely to be unequal. This is in part due to the binary 
nature of the individual components of the TWC.   
 
The ability to predict intravenous corticosteroid therapy failure was poor using either inflammatory 
marker platform. Those patients satisfying two TWC had higher response rates to corticosteroid 
therapy than patients satisfying three criteria. This may reflect the original choices of clinical 
criteria and cut offs by Sidney Truelove with the goal being the identification of patients at high risk 
of colectomy. 
 
Faecal calprotectin 
There were no statistically significant differences in the faecal calprotectin concentrations between 
ESR>30 and CRP≥12 allocated TWC severity groups (Figure 1.7).  Factors contributing to these 
findings include the reduced patient numbers with available admission faecal calprotectin data 
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(n=57) and the lack of a standardised protocol for faecal specimen collection during the course of 
this study.  
 
These data support the idea that this quantitative test is better suited to determining the presence of 
any significant inflammatory disease activity from remission rather than differentiating between 
moderate and severe disease activity states.27  
  
 
Critique 
Strengths of this investigation include the large number of patients included with severe UC. This 
series reflected a real-world cohort of consecutive inpatient acute UC cases. Objective measures of 
disease activity in addition to clinical outcomes were compared refuting significant differences 
between the ESR and CRP-defined groups.  
 
Limitations of this study include the long study duration. Whilst the treatment of acute severe UC 
has evolved extensively over the last two decades, the initial three days of therapy has remained 
remarkably consistent since the mid-1970s. Other consistencies of this study include the limited 
pool of two treating IBD clinicians, the application of a heavily protocolised inpatient management 
algorithm and the exclusion of patients with recent biologic therapy.  
 
Whilst this exclusion may initially seem to limit the external validity of the findings, it was an 
important feature of the study protocol. The experience in our centre is that symptomatic patients 
admitted with a secondary loss of response to biologic therapy have a tendency to take a 
corticosteroid responsive course. This group usually display lower levels of systemic toxicity at 
presentation. This is probably in part due to a continued partial response to biologic therapy and 
earlier presentation secondary to engagement with healthcare providers.  
 
Study cohort limitation 
For the purpose of increasing the robustness of the data for publication the cohort was limited to 
cases presenting to the Royal Brisbane and Women’s Hospital only. This was to increase the 
consistency of the laboratory results by removing bias that could be introduced by the use of 
different inflammatory marker testing platforms at other facilities. The risk of recall bias of clinical 
data from peripheral sites was also limited by taking this approach. See Appendix A for the analysis 
of the unrestricted n=270 cohort including moderately severe cases and those cases transferred from 
other facilities. 
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As the cut off finding approach was used in preference to the previously trialled but insufficiently 
precise direct statistical relationship approach (see Appendix A), the importance of including the 
moderate UC cases was diminished.  
 
As encountered in this study, cases of TWC moderate UC often present with inflammatory markers 
within the normal range. As the inclusion of these moderate UC cases will influence the rate of true 
positives and negatives and potentially be controversial to examiners and reviewers, this group was 
also removed from the study cohort.   
 
Clinical relevance 
This work may influence clinical practice by relegating ESR as a necessary admission blood test in 
acute presentations of UC. Utilising the CRP-based criteria will improve accessibility to the clinical 
information required for time critical decision making regarding patient disposition and acute 
management. The primary study finding also supports the paradigm that in inflammatory diseases 
that are known to be poor inducers of CRP production, a mildly elevated CRP between two and 
three times the upper limit of normal may be an indicator of a clinically significant inflammatory 
burden. Finally, the inclusive nature of the CRP criteria will enhance access to infliximab in 
healthcare settings where satisfying the TWC is mandatory for reimbursement. 
 
In summary, a CRP threshold of  ≥12mg/L was found to be an inclusive and sensitive cut off that 
when incorporated into the Truelove and Witts criteria, replacing the traditional ESR >30mm/h 
criterion, had similar performance characteristics when applied to the assessment of acute UC 
disease activity.    
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  Chapter 2 
 
The influence of systemic immunosuppression by non-biological agents on markers of systemic 
inflammation in acute ulcerative colitis 
40 
 
2.1 Literature review 
 
The use of systemic immunosuppression as a corticosteroid sparing strategy is common in UC. In a 
recent clinical audit, rates of immunomodulator use in Australian UC patients were reported to be 
40% (IQR 20-55%).28  
 
There are a number of putative mechanisms by which immunosuppressants can affect inflammatory 
marker levels. As already alluded to in the previous chapter, immunosuppression with the 
thiopurines and methotrexate, can increase mean corpuscular volume (MCV). An increase in MCV 
is known to increase both erythrocyte agglutination and sedimentation rates.7  
 
With respect to the most frequently prescribed thiopurine class, including azathioprine, 6-
mercapturine and 6-thioguanine, the exact therapeutic mechanism(s) of action is still poorly 
understood despite over 50 years of study. Broadly, these agents and their metabolites work to 
attenuate pro-inflammatory processes through antimetabolite (6-methylmercaptopuirne) and the  
relatively quick-acting proapoptotic (6-thioguaninie nucleotide) processes.29  With the latter process 
predominantly acting on activated T-lymphocytes, it is highly likely that there will be some 
influence on the important inducers of CRP production such as IL6, IL-1β and TNFα, known to be 
produced by this cell class.  
 
Perhaps surprisingly, given the clinical importance of systemic inflammatory markers in disease 
activity assessment and prognostication, there are limited data specific to the IBD sphere available 
to answer this question. The prevailing expert opinion in this field is that non-biologic 
immunomodulator and anti-inflammatory agents at therapeutic doses do not directly influence CRP 
levels.30-32  
 
The true pharmacodynamic situation may, in fact, be more nuanced. Calcineurin inhibitors and 
corticosteroids have been associated with a blunted CRP response in acute renal transplant 
rejection.33 However, a prompt CRP response is preserved when bacterial infection occurs after 
transplant. Conversely, azathioprine treated patients routinely produce a CRP response to acute 
graft rejection.34 The proposed mechanism for this selectivity is the specific blocking of IL-1 
production by cyclosporine. 
 
One of the few relevant studies in the IBD field found 11 (9%) patients treated with a thiopurine 
had persistently elevated ESR with a normal CRP in the setting of asymptomatic disease.35 
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However, the significance of the findings in this study of 120 paediatric subjects is limited by the 
fact the majority of participants were in clinical remission and were assigned a diagnosis of Crohn’s 
disease (79%). 
 
Another noteworthy observation from this study is that those individuals with discordant results 
(elevated ESR and normal CRP) had a higher mean MCV than the participants with concordant 
inflammatory marker levels. This observation reached statistical significance (p=0.0373). Whilst the 
numbers in the discordant group were small, these findings suggest an association between 
discordantly low CRP levels and a known thiopurine effect on erythrocytes in the setting of 
established immunomodulatory therapy.  
 
Effect of established immunomodulator use on risk of colectomy   
A key early piece of evidence is the large retrospective series presented by Moskovitz that reported 
an experience with cyclosporine for corticosteroid-refractory acute UC.36 A disparity in the 
colectomy rate by immunomodulator status on admission was found with immunomodulator 
treatment rates being 46% in patients requiring colectomy-by-discharge versus 28% of those treated 
non-operatively (p=<0.01). As many as 88% of patients established on azathioprine at the time of 
presentation underwent a colectomy within 12 months of presentation.  
       
Whilst other observational studies of colectomy-by-discharge rates following rescue therapy have 
not shown this effect, 20 the Moskovitz study and other concordant studies continue to influence the 
choice of rescue agent in clinical practice.37  
   
More recent studies in the entire severe UC population from our centre with ciclosporin or 
infliximab rescue do not show this effect on colectomy risk for immunomodulator or oral 
corticosteroid exposure at the time of admission, OR 0.76 (0.37 - 1.49), 1.2 (0.65 - 2.19), 
respectively.38  
 
Other inflammatory disorders 
Much of the published work in this field has focussed on presentations of infection in patients with 
systemic lupus erythematosus (SLE) on immunosuppressant therapy. Unless complicated with 
serositis, active SLE, like UC, dermatomyositis and Sjögren’s syndrome, is known to produce lower 
CRP levels than active Crohns or rheumatoid arthritis.39 Relevant differences between SLE and UC 
include the much higher rate of both hepatic pathology and interferon-α production. There is 
evidence that both of these processes lead to a decreased rate of CRP production.40 There was no 
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statistically significant relationship found between CRP level and the use of either 
immunosuppressants or corticosteroids in 193 patients with SLE subsequently found to be 
harbouring a bacterial infection.41 
 
A retrospective Canadian study of 839 individuals investigating the causes of all presentations with 
CRP levels >100mg/L (55% infections, 2.5% IBD presentations) did observe a trend towards a 
reduction in CRP levels in the 21 patients on anti-TNFα and not other agents.42 This observation 
was not reported to reach statistical significance as it was limited by overlapping medication 
exposure to different classes of immunosuppression.  
 
In summary, the current expert opinion is that CRP is not affected by immunomodulator use in IBD 
patients. However, there is limited evidence in the IBD field and instances in other inflammatory 
states that refute this position. More data are needed to address this relevant clinical question. 
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2.2 Aim 
 
To analyse acute UC presentation data to evaluate for any effect of systemic immunosuppression on 
inflammatory marker levels.  
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2.3 Hypothesis 
 
In presentations of acute UC there will not be a statistically significant effect of systemic 
immunomodulator use on levels of commonly used markers of systemic inflammation. 
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2.4 Methods 
 
      Patients 
To be eligible for study inclusion individuals had to have a confirmed clinical and histological 
diagnosis of UC of at least 90 days duration at the time of hospital presentation to a single 
tertiary centre with moderate-severe UC according to the TWC. A paired ESR and CRP 
collected within 24 hours of admission was also mandatory for inclusion. Written informed 
consent was obtained from all patients included in this study and the study protocol approved by 
the Royal Brisbane and Women’s Hospital medical ethics committee. 
 
Patients on immunomodulators, oral corticosteroid and/or 5-aminosalicylates at the time of 
admission were included in the study.  Patients were considered to be taking an 
immunomodulator if they had been on a thiopurine with therapeutic drug levels for four months 
or more prior to presentation or were taking methotrexate for the same duration. For the purpose 
of maintaining consistency across the cohort, those patients on any biologic therapy at the time 
of admission were excluded.  
 
Laboratory tests 
ESR tests were performed on the Ves-matic Junior 20 (Diesse Diagnostica Senese, 
Monteriggioni, Italy). CRP was assessed on the Roche-Hitachi 747 Analyzer (Roche 
Diagnostics, Mannheim, Germany, 1996-2008) and the Beckman-Coulter DxC 800 Analyzer, 
(Beckman-Coulter, Fullerton, USA, 2008-2017) platforms. 
 
 Statistics 
R version 3.4.0 “You Stupid Darkness” (R: A language and environment for statistical         
computing. R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses. 
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2.5 Results 
 
349 presentations with moderate-severe UC resulting in hospital admission were assessed. 158 
had an established diagnosis of UC of ≥90 days as well as paired ESR and CRP collected within 
24 hours of admission (Table 2.1). Eighty-seven (54%) of patients were male. Forty-three 
individuals (27%) were on immunomodulators for ≥4 months prior to presentation. Of these 22 
were taking 6-mercaptopurine, 19 were taking azathioprine, one patient was taking 6-
thioguanine and one oral methotrexate.  
 
There were no statistically significant differences in the proportions of patients separated by 
immunomodulator status between the groups allocated by the number of TWC satisfied at 
admission (Figure 2.1). This included the rate of prednisone use at admission. The median dose 
of prednisone on presentation was 40mg and 32.5mg per day in immunomodulator naïve and 
immunomodulator positive groups, respectively. 
 
 
Figure 2.1 Patients separated by immunomodulator status and number of TWC satisfied at 
admission. 
TWC: Truelove and Witts criteria; IM: immunomodulator 
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Table 2.1 Patient details separated by immunomodulator status  
  Total IM naïve IM p-value 
n (%)  158 115 (73) 43 (27)  
      
Gender (%) M 85 (54) 59 (51) 26 (60) 0.4 
 F 73 (46) 56 (49) 17 (40)  
Age at time  33 (26-43) 33 (26-42) 34 (27-43) 0.64 
Disease duration in years  4 (2-10) 4 (2-10) 4 (2-11) 0.75 
Disease extent (%) E1-E2 60 (38) 47 (41) 13 (30) 0.3 
 E3 98 (62) 68 (59) 30 (70)  
TWC activity (%) Moderate 21 (13) 15 (13) 6 (14) 1 
 Severe 137 (87) 100 (87) 37 (86)  
Prednisone on admission (%) 76(48) 51(44) 25(58) 0.17 
Prednisone dose 
(mg)†  
 40 (25-50) 40 (25-50) 32.5 (20-50) 0.3 
      
ESR   40 (26-56) 41 (27-58) 40 (24-53) 0.62 
CRP  47 (15-95) 50 (18-97) 29 (11-89) 0.25 
Albumin*  34 (6) 33 (6) 34 (5) 0.72 
Haemoglobin* 121 (22) 122 (22) 120 (22) 0.74 
MES~ MES 0 2 1 1 0.89 
 MES 1 9 8 1  
 MES 2 46 29 17  
 MES 3 55 38 17  
 
IM: immunomodulator; IQR: interquartile range; ESR: erythrocyte sedimentation rate, CRP: C-
reactive protein; MES: Mayo endoscopic subscore; TWC: Truelove and Witts criteria. Unless 
otherwise specified all values are expressed as medians with interquartile ranges. †n=112 for IM 
naïve, n=42 for IM. *Mean and standard deviation. ~MES n=112. Disease extent as per the 
Montreal classification. 
 
Mann-Whitney U-test revealed no statistically significant correlation between immunomodulator 
use and CRP (p=0.25) or ESR at presentation (p=0.62).  
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Figure 2.2 ESR on presentation separated by immunomodulator use status 
ESR: erythrocyte sedimentation rate; IM: immunomodulator 
 
 
Figure 2.3 CRP on presentation separated by immunomodulator use status 
CRP: C-reactive protein; IM: immunomodulator 
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The effect of oral corticosteroids on markers of systemic inflammation at presentation 
A similar analysis of the effect of oral corticosteroids at admission was performed. There were no 
statistically significant differences found in inflammatory marker levels on the basis of oral 
corticosteroid intake status on presentation. The uncorrected p-values were p=0.39 and 0.26 for 
ESR and CRP, respectively.  
 
 
The effect of disease extent on markers of systemic inflammation at presentation 
A similar analysis of disease extent was performed. There were no statistically significant 
differences found in inflammatory marker levels on the basis of disease extent. The uncorrected p-
values were p=0.15 and 0.72 for ESR and CRP, respectively. The two proctitis cases (E1) were 
included with the left-sided (E2) cases for this analysis. 
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2.5 Discussion 
 
The main finding of this prospective observational study is that systemic immunosuppression with 
non-biologic agents did not significantly affect the levels of systemic markers of inflammation at 
the time of presentation in established cases presenting with acute moderate-severe UC.  
 
Strengths of this study include prospective data collection, sample size, consistencies between 
patient groups split by immunomodulator status, collection of oral corticosteroid data, consistencies 
of clinical and laboratory assessment, the inclusion of patients with moderate colitis and the 
exclusion of patients on biologic agents.  
 
Restricting study eligibility to established cases of UC was performed for two key reasons. Firstly, 
it was to allow for an appropriate comparison between like groups.  
 
The likelihood of incident UC cases also being on systemic immunosuppression for another 
indication is low. This will result in the preferential allocation of incident cases to the 
immunomodulator naïve group causing bias. Additionally, a patient having a diagnosis for more 
than 90 days will have a lower likelihood of being assessed during their index flare.  
 
Whilst the exclusion of patients on biologic therapy may initially seem to limit the external validity 
of the findings, it was an important feature of the study protocol. It removed the potent influence of 
these agents on inflammatory markers at presentation.  
 
Of interest, a preliminary analysis with a larger sample (n=270) including index presentations and 
patients transferred from other hospitals (using presentation data from the transferring facility) did 
find a statistically significant lower CRP but not ESR in immunomodulator users (see Appendix A). 
This observation was not found to have statistical significance following the application of robust 
regression with Huber weighting. 
 
Shortcomings of this study include the change in CRP analyser during the study period. An 
assessment of machine batch effect was not evaluated.  
 
Other indices that might affect ESR in particular, other inflammatory disorders, mean corpuscular 
volume and haematocrit were not incorporated in the analysis.39, 43 The observation that there were 
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no statistically significant differences between immunomodulator status cohorts in gender, 
haemoglobin and albumin concentrations is a reassuring finding. 
 
On the level of the individual patient, the serial CRP concentration is one of the few informative 
and objective measures of disease acuity and treatment response that will alter management during 
the hospital admission.26, 44 This study provides the previously lacking reassurance that baseline 
immunosuppression status need not be taken into account when interpreting the ESR or CRP levels 
on presentation in established UC patients not on biologic therapy. 
 
As many of the IBD severity and prognostic indices in contemporary use incorporate either the ESR 
or CRP as objective markers of disease acuity, this study has high translatability to patients with a 
secure diagnosis of UC not in their initial flare.4, 25, 26  
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Chapter 3 
 
The derivation of a risk algorithm predicting failure of intravenous corticosteroid therapy in 
acute ulcerative colitis from clinical criteria available on presentation 
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3.1 Literature review 
 
In the setting of acute UC intravenous corticosteroid therapy has a response rate of between 50-
70%.45 The response rate is subject to many variables including the definition of acute UC, local 
protocols relating to timing of implementation of second-line therapies, and the definition of an 
adequate clinical response to therapy. Variations in these parameters have hindered meta-analyses 
and direct inter-study comparisons between these predominantly observational studies.  
 
Since the 1970s there have been many UC activity indices formulated and extensively reviewed 
elsewhere.5, 6, 45 Few have been validated in prospectively collected patient cohorts and at least four 
offer a risk score on the likelihood of colectomy-by-discharge. These are the Oxford26, Swedish44, 
Seo46 and Ho25 indices. These indices use clinical parameters present or collated up to day three of 
intravenous corticosteroid therapy (Table 3.1).  
 
Table 3.1 Prognostic indices for acute UC47 
 
There is a dearth of prognostic scores that have been trained to use variables available at the time of 
presentation to predict clinical outcomes during the admission. As will be discussed in more detail 
below, this is, in part, due to the focus on the outcome of colectomy-by-discharge. 
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Exceptions include a retrospective study in abstract form from Edinburgh.48 It derived a risk score 
for colectomy-by-discharge based on data from admission and day three of corticosteroid therapy. It 
was found that colectomy-by-discharge was predicted by extensive disease, albumin <30g/L and 
CRP ≥20 mg/L on admission, and albumin and stool frequency at day three. This study also 
addressed corticosteroid therapy response and found that 71% of those who satisfied two or less of 
the criteria at admission responded adequately to corticosteroids and avoided treatment escalation.  
 
A prospective study of 89 acute severe UC presentations to Oxford showed that rescue therapy was 
required in 11/14 (79%) cases with an ulcerative colitis endoscopic index of severity (UCEIS) of 
>6/8.49 
 
Jain et al reported a small prospective study of 49 acute severe UC patients.50 Patients with a 
UCEIS score of >6/8 at admission combined with a day three faecal calprotectin of >1000μg/g 
uniformly failed intravenous corticosteroid therapy. It was of interest that CRP at admission or on 
day three and admission faecal calprotectin were not identified as independent risk factors for 
subsequent corticosteroid therapy failure.  
 
Two older studies, also from India were designed to prospectively assess for early parameters 
predicting intravenous corticosteroid treatment failure.51, 52 One assessed 55 consecutive acute UC 
presentations from 50 patients.52 Only ten of the 55 did not respond to corticosteroid therapy. After 
multivariate analysis haemoglobin <90g/L, CRP >18.6mg/L, prothrombin time >1.4 and fibrinogen 
<22mg/L independently predicted corticosteroid therapy failure with AUCs between 77 and 80%. A 
logistic regression approach combining these parameters was not undertaken in this study. 
 
Another study of 30 patients from the mid-1990s treated cases with intravenous corticosteroids for a 
mean of 9.2  days (range 2-20) with a response rate of 60%.51 It found that the admission 
parameters of stool frequency ≥9 per day, pulse rate ≥120/minute, temperature ≥38°C, albumin ≤ 
20g/l, mucosal tags on plain x-ray abdomen and extensive colitis predicted a poor response to 
corticosteroid therapy. 
 
Much more recently, a study in abstract form from Melbourne has identified an admission faecal 
calprotectin of >1645μg/g and CRP to albumin ratio (CAR) of >1.34 as being highly predictive of 
corticosteroid therapy failure with a 96% PPV.53 
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The changing face of acute ulcerative colitis treatment outcomes 
The success of corticosteroid therapy was classically defined as avoidance of colectomy-by-
discharge or colectomy within a defined timeframe of hospital admission. The advent of rescue 
medical therapy in the 1990s interrupted the progression between corticosteroid failure and 
immediate referral for colectomy. Despite this protocol change, a 2007 meta-analysis indicated 
colectomy-by-discharge rates had remained constant at around 27% between the 1970s and the 
early 2000s.45 The analysis of the 2008 and 2010 UK IBD audit data revealed colectomy rates of 
19% and 17% respectively. However, due to a lack of ESR data, the inclusion criteria for severe 
colitis included a CRP of >10mg/L. Additionally, no haemoglobin data were available for the 2010 
cohort.11  
 
Despite these omissions, there appears to be a trend towards lower colectomy by discharge rates in 
the UK coinciding with the widespread uptake of rescue medical therapy and the addition of 
infliximab to the armamentarium for this indication in the late 1990s. This decrease may in part be 
due to the observed effect of a delay to the timing of an ‘inevitable’ colectomy following the 
institution of rescue therapy.3, 26, 54 Medium to long term data reveal an ongoing risk of colectomy in 
the recently discharged severe UC patient group. This risk being most marked up to two years from 
the severe UC admission.2, 55 
 
With a reduction in colectomy-by-discharge rates, the maturing of rescue medical therapy and the 
increasing availability and use of maintenance biologic therapy, the progression from corticosteroid 
therapy failure to early colectomy has been irrevocably disrupted. Concomitantly, advances in 
severe UC treatment success rates also influence the relationship between clinical indices observed 
early during the admission and the resulting colectomy-by-discharge outcomes. 
 
In contrast, a clinical outcome that has remained relatively constant during this time is that of 
failure of corticosteroid therapy. Overall this rate is approximately 40% when inclusion criteria are 
restricted to patients with severe UC activity as defined by the TWC.45 This is in part due to the 
consistency of the recommended corticosteroid regimen established in the mid-1970s. In most first 
world settings it comprises a total daily intravenous dose of 400mg hydrocortisone or 60mg 
methylprednisolone or equivalent dose of corticosteroid for a minimum of five days.56 
 
Assessing response to corticosteroid therapy 
Appropriately, the definition of corticosteroid therapy failure is usually a clinically driven decision. 
This decision is likely to have poor inter-observer agreement, although this has never been tested. 
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The Day 3 (Oxford) criteria is the tool that has had a profound impact on clinical decision making 
for this presentation.26 It is an assessment of corticosteroid response applied on the third calendar 
day of intravenous corticosteroid therapy. If at this stage the bowel frequency is >8 or 3-8 per day 
with a CRP of >45mg/L then the risk of subsequent colectomy during the admission was found to 
be 85%. This high positive predictive value lays solid grounds for treatment escalation. 
 
The Oxford criteria were derived from 51 presentations of TWC severe UC with 14 proceeding to 
rescue therapy with cyclosporine. A total of 15 (29%) patients underwent colectomy during the 
admission. In keeping with the contemporary practice and the disease severity of individual cases, 
eight of the colectomy cases were not administered rescue therapy. Another observation of this 
study was the high colectomy-by-discharge rate in cyclosporine treated individuals with only 7/14 
and 4/14 avoiding colectomy during the admission and at study completion with a median follow-
up of 12 months, respectively.  
 
Additionally, intravenous corticosteroids were continued for up to eight days in total prior to the 
commencement of rescue therapy. This is one of a number of era-related protocol components that 
may have contributed to the higher colectomy-by-discharge rate than we see in contemporaneous 
series. Long-term follow up data did show a trend towards lower colectomy rates within four years 
of presentation for those administered cyclosporine therapy within five days or less of intravenous 
corticosteroids versus those commenced after more than five days of intravenous corticosteroids.55 
This observation did not reach statistical significance by Log-rank test. 
 
Despite the changes wrought by improvements in contemporary severe UC practice, the Oxford 
criteria retains its utility as a hurdle for continuing with intravenous corticosteroids versus treatment 
escalation. Whilst this practice may seem somewhat dated, continuing to follow this paradigm 
enhances the consistency between practitioners and hence between published series that strictly 
apply this clinical decision making tool. 
 
A recent comparison of the accuracy of established risk scores (MES, Oxford, Edinburgh, Swedish) 
did analyse clinical outcomes including intravenous corticosteroid failure, rescue therapy 
administration and colectomy-by-discharge.57 For all clinical endpoints the Swedish score had the 
highest AUC. In this Portuguese study of 112 TWC qualifying severe UC patients, corticosteroid 
treatment failure was defined by a clinical as opposed to a criteria-led decision for escalation to 
rescue medical therapy or surgery. 
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Figure 3.1 ROC curves for four risk prediction scores for the clinical outcomes of rescue therapy, 
colectomy-by-discharge and corticosteroid treatment failure.57  
 
Whilst this study presented a useful comparison between a large retrospective series of severe UC 
patients, the fact that these risk scores predominantly utilise day three indices limits the validity of 
these results to the question of predictive indices assessable on presentation. 
 
A paradigm shift: The utility of a continuous risk score for corticosteroid therapy failure as an 
index of disease activity 
The Truelove and Witts paradigm of classifying disease severity into ordinal assignations of mild, 
moderate and severe disease activity has influenced subsequent iterations of UC activity indices. 
Whilst this scale continues to be a useful guide for patient disposition in acute UC presentations, a 
significant proportion of cases requiring admission on clinical grounds for intravenous 
corticosteroids do not meet the severe UC criteria.  
 
Continuous risk scores such as the Swedish and Seo indices do address this issue. However, the Seo 
index also allocates patients into one of three ordinal groups based on activity. Despite having a 
reported 97% negative predictive value for colectomy at 72 hours, this index has not had 
widespread uptake and in one study its agreement with an expert clinician’s judgement was only 
47%.58 The Swedish fulminant colitis index, like the Day 3 (Oxford) criteria is focussed on 
identifying those with a high risk of colectomy as opposed to being a global activity index.  
 
There are other precedents for continuous risk scores linked with clinical outcomes elsewhere in the 
fields of gastroenterology and hepatology. One of the most successful is the Model for End-stage 
Liver Disease (MELD) score. It is widely used to determine appropriateness and priority for 
orthotopic liver transplant.59  
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The MELD score was a slight alteration to a risk score already derived from 231 cirrhotic patients 
for predicting patient survival post elective trans-jugular intrahepatic portosystemic shunt (TIPS) 
insertion.60 It incorporated the international normalised ratio (INR), total serum bilirubin and 
creatinine to determine the three month mortality risk. The formula was then slightly altered and 
validated on a large and heterogeneous series of cirrhotic patients. The derived score is discretised 
into MELD score bands (≤9, 10-19, 20-29, 30-39, ≥40) with associated increasing rates of three 
month mortality. 
 
The benefits of a validated continuous risk score include the ability to prognosticate an individual’s 
risk of a defined outcome based on clinical variables that are proven discriminators without having 
to assign patients into risk categories. This allows the clinician to personalise subsequent 
management decisions. 
 
In the context of severe UC the foreknowledge of a symptomatic patient’s chance of responding to 
intravenous corticosteroids is useful. This knowledge can be used as background for decision 
making regarding the requirement for, timing and type of treatment escalation. It could give the 
clinician an evidence base for a more definitive, top-down treatment approach avoiding sequential 
therapy and potential side effects of immunosuppression with multiple concurrent agents.61, 62 There 
is also the potential for improved early colectomy avoidance and post-colectomy outcomes with the 
institution of rescue therapy prior to the current day 3-5 paradigm.55 Finally, the identification of 
outpatients at high risk of complications will help guide both clinical decision making and patient 
acceptance of escalations of care such as hospital admission. 
 
In summary, colectomy-by-discharge rates for severe UC have changed with the adoption of 
advances in rescue therapy protocols. Conversely, rates of corticosteroid response have remained 
relatively constant. The latter is a useful clinical outcome forming the basis of a risk score that will 
be able to assess disease activity at the moderate-severe end of the activity spectrum and potentially 
influence the acute management of these cases. 
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3.2 Aims 
 
 To use clinical data from acute UC presentations obtainable within 24 hours of admission to 
identify clinical parameters that independently predict the failure of corticosteroid therapy. 
 
 Employ these parameters to derive a continuous risk score for failure of intravenous 
corticosteroid therapy for acute UC.  
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3.3 Hypothesis 
 
Risk factors for the failure of corticosteroid therapy present at admission are likely to include: 
elevated CRP, ESR, bowel frequency; decreased albumin concentration; current corticosteroid and 
systemic immunosuppressant usage status and may not include all of the TWC parameters. 
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3.4 Methods 
 
Patients 
As part of the inflammatory bowel disease (IBD) program commencing in 1996, all subjects 
admitted to the Royal Brisbane and Women’s Hospital with any complications of IBD, 
including an acute flare of their disease, are referred to the IBD team. Data on these admissions 
have been prospectively collected on a dedicated software platform, IBD Prime. Patients 
included in this study were 349 consecutive admissions between 1996 and 2017 with acute UC 
requiring hospital admission. Repeat presentations by the same individual within a 12 month 
period of the initial presentation were excluded. Written informed consent was obtained from all 
patients included in this study and the study protocol approved by the Royal Brisbane and 
Women’s Hospital medical ethics committee. 
 
 
Figure 3.2 Progression of statistical analysis for clinical and endoscopic risk scores. *Data set 
was incomplete for ESR (n=270), MES (n=275) and faecal calprotectin (n=166). 
 
Patients on concomitant immunomodulator, oral corticosteroid and/or 5-aminosalicylates at the 
time of admission were included in the study.  Patients were considered to be taking oral 
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corticosteroids if they presented with a >24 hour history of oral corticosteroid administration 
prescribed for UC. Patients were considered to be taking an immunomodulator if they had been 
on a thiopurine with therapeutic drug levels for four months or more prior to presentation or 
were on methotrexate for the same duration. For the purpose of maintaining consistency across 
the cohort, those patients on biologic therapy at the time of admission were excluded. 
Maintenance infliximab for refractory or corticosteroid dependent moderate-severe UC was first 
reimbursed by the Pharmaceutical Benefits Scheme (Australian Commonwealth Government 
payer) in 2015. 
 
The diagnosis of UC was confirmed by histology together with endoscopic, radiological and 
clinical correlation. Patients were treated with a standardised treatment protocol by one of two 
subspecialist IBD physicians.3 The Day 3 and Day 7 (Oxford) criteria were used to determine 
corticosteroid treatment failure.26 When indicated a choice of surgery or rescue therapy initially 
with intravenous cyclosporine A (1999-) and later with infliximab (2001-) was offered.  The 
choice of rescue agent and/or surgery when appropriate was made in close collaboration with 
the patient. 
 
Laboratory tests 
ESR tests were performed on the Ves-matic Junior 20 (Diesse Diagnostica Senese, 
Monteriggioni, Italy). CRP was assessed on the Roche-Hitachi 747 Analyzer (Roche 
Diagnostics, Mannheim, Germany, 1996-2008) and the Beckman-Coulter DxC 800 Analyzer, 
(Beckman-Coulter, Fullerton, USA, 2008-2017) platforms. 
 
Statistics 
R version 3.4.0 “You Stupid Darkness” (R: A language and environment for statistical         
computing. R Foundation for Statistical Computing, Vienna, Austria) was used for all analyses. 
Statistics 
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3.5 Results 
 
Data from 349 presentations of acute UC admitted to hospital for intravenous corticosteroid therapy 
generated by 327 individuals were interrogated. The dataset was incomplete for some variables 
(Table 3.3). A total of 17 variables were assessed with univariate analysis to determine statistically 
significant differences between responders and non-responders to corticosteroid therapy. 
 
Raw data 
Of the 349 presentations, 188 (54%) were male. The median age of presentation was 33 (IQR 24-
46). Extensive disease predominated with 234 (67%) having Montreal classification E3 disease. 
Median disease duration was two years (IQR 0.25-7.21) with 90 (26%) of presentations being the 
first presentation of IBD. In all, 141 (40%) met the predefined criteria for complete clinical 
response to intravenous corticosteroid therapy while 208 (60%) did not respond.  
 
At the time of presentation 151 (43%) of patients were taking oral corticosteroids whilst only 80 
(23%) were on systemic immunosuppression for more than four months. The median dose of oral 
prednisone on presentation was 40mg (n=102, IQR 25-50mg) in the corticosteroid therapy failure 
group and 40mg (n=43, IQR 30-50mg) in the responders (p=0.29).  
 
Univariate analysis  
Seven variables were statistically disparate between corticosteroid therapy responders and non-
responders after familywise error correction for multiple comparisons using the Bonferroni method. 
These were disease extent (extensive versus not extensive; p=0.0046), disease duration (p=0.017), 
oral prednisone therapy on admission (p=0.0048), ESR (p=0.036), CRP (p=0.011), haemoglobin 
(p=0.026), albumin (p=6.85e-6), Mayo endoscopic subscore (MES; p=1.21e-8). 
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Table 3.2 Patient characteristics by corticosteroid therapy response status 
 Total  
(IQR, %) 
Responder 
(IQR, %) 
Failure  
(IQR, %) 
p-value Corrected p-
value* 
N  349 141 (40) 208 (60)   
Male gender  188 (54) 68 (48) 120 (58) 0.1 1 
Age   33 (24-46) 32 (24-47) 34 (25-44) 0.68 1 
Extent: E1-E2  114 (33) 62 (44) 52 (25) 0.00027 0.0046 
              E3  234 (67) 78 (56) 156 (75)   
Disease duration (years) 2 (0.25-7.21) 2.1 (1-9) 1.7 (0.1-5.4) 0.001 0.017 
First UC episode 90 (26) 25 (18) 65 (31) 0.007 0.12 
Oral prednisone   151 (43) 44 (31) 107 (51) 0.00028 0.0048 
Immunomodulator  80 (23) 32 (23) 48 (23) 1 1 
       
Bowel frequency  10 (8-15) 10 (7-13) 10 (8-15) 0.028 0.48 
ESR (n=270) 42 (27-59) 37 (24-48) 47 (30-63) 0.0021 0.036 
CRP  55 (21-112) 39 (11-100) 62 (28-122) 0.00063 0.011 
Temperature  37 (36.7-37.4) 37 (36.6-
37.4) 
37 (36.7-37.5) 0.24 1 
Pulse Rate  88 (76-98) 88 (80-99) 88 (75-96) 0.21 1 
Haemoglobin  122 (106-138) 127 (109-
140) 
118 (103-134) 0.0015 0.026 
Albumin   32 (28-36) 34 (30-37) 30 (26-35) 4.03e-7 6.85e-6 
       
Number of TWC  0 7 (2) 6 (4) 1 (1) 0.029 0.49 
 1 35 (10) 21 (15) 14 (7)   
 2 163 (47) 58 (41) 105 (50)   
 3 94 (27) 42 (30) 52 (25)   
 4 44 (13) 12 (9) 32 (15)   
 5 5 (1) 1 (1) 4 (2)   
       
Faecal calprotectin 
(n=166) 
 2100 (1025-
3795) 
1600 (860-
3000) 
2500 (1300-
4400) 
0.0085 0.14 
       
MES (n=275)      
MES 0 0 2 (1) 2 (2) 0 (0) 7.15e-10 1.21e-8 
MES 1 1 15 (5) 12 (11) 3 (2)   
MES 2 2 122 (44) 64 (60) 58 (34)   
MES 3 3 136 (49) 30 (32) 108 (64)   
UC: ulcerative colitis; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TWC: 
Truelove and Witts criteria; MES: Mayo endoscopic subscore. Immunomodulator use included: 
azathioprine, 6-mercaptopurine, 6-thioguanine and methotrexate therapy for ≥4 months. *P-values 
corrected for familywise error using the Bonferroni method. 
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Stepwise logistic regression models 
 
Partial (clinical) risk score for corticosteroid therapy failure 
Clinical variables not reliant on an endoscopic evaluation that were statistically correlated with 
corticosteroid non response and additional variables included in the TWC were assessed in a 
multivariate general linear model.  To identify the minimum data required to predict corticosteroid 
non response, stepwise regression was then applied to this model. The variables entered into the 
equation were: disease duration, oral prednisone therapy on admission, ESR, CRP, haemoglobin, 
albumin, bowel frequency, body temperature, pulse rate. A complete data set of n=270 was 
available for this analysis. 
 
Following stepwise logistic regression the variables in the model were reduced to disease duration, 
bowel frequency, albumin, oral prednisone on admission, and CRP.  
 
The removal of ESR from the variables in this model allowed the training dataset to be expanded to 
n=349. The logistic regression model was rerun with the five listed variables in the larger data set 
producing the following result. 
 
Partial (clinical) risk score for corticosteroid therapy failure =  
 
0.0971890 - 0.2446537Oral prednisone on admission - 0.0116896Bowel frequency  
- 0.0004597CRP(mg/L) + 0.00.0171600Albumin(g/L)  +  0.0079754Disease duration (years)   
 
Validation and testing 
Leave-one-out cross validation was performed.  
 
The partial risk score for corticosteroid therapy failure algorithm was applied to the data set of 349 
individuals with available data generating 349 score results (Table 3.3). Each result was assessed as 
a potential cut off or threshold for defining patients at high risk for corticosteroid therapy failure. As 
expected, increasing the threshold score used to define corticosteroid failure (thus including more 
individuals with a lower risk score result) reduced the positive predictive value of the algorithm 
(Figure 3.3).  
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A threshold score of 0.305 produced an 80% PPV for corticosteroid failure. This threshold 
decreased to 0.234, 0.179 and 0.151 for 85%, 89% and 92% PPVs for corticosteroid failure, 
respectively. 
 
Table 3.3. Partial risk of corticosteroid therapy failure logistic model cut offs at various PPV 
intervals 
Threshold Sensitivity Specificity Accuracy PPV NPV % of cases 
0.151 0.163462 0.978723 0.492837 0.918919 0.442308 11 
0.179 0.225962 0.957447 0.52149 0.886792 0.456081 15 
0.234 0.293269 0.921986 0.547278 0.847222 0.469314 21 
0.305 0.403846 0.851064 0.584527 0.8 0.491803 30 
PPV: positive predictive value; NPV: negative predictive value; % cases: the percent of the total 
number of cases below the corresponding threshold  
 
The 80%, 85%, 89% and 92% PPV thresholds encompassed 30%, 21%, 15% and 11% of the 349 
presentations, respectively.  
 
Figure 3.3 PPV for corticosteroid therapy failure at various thresholds of partial risk of 
corticosteroid failure scores (n=349). PPV: positive predictive value. 
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Full risk score for corticosteroid therapy failure 
Statistically significant clinical variables in addition to the remaining variables contributing to the 
TWC were assessed in a stepwise logistic regression model on the basis of response or non-
response to corticosteroid therapy. The variables entered into the equation were: disease duration, 
oral prednisone therapy on admission, ESR, CRP, haemoglobin, albumin, bowel frequency, body 
temperature, pulse rate, Mayo endoscopic subscore and disease extent. A complete data set with 
n=204 was available for the stepwise analysis. 
 
Following application of the stepwise logistic regression model the variables remaining in the 
model were reduced to: bowel frequency, CRP, albumin, oral prednisone on admission and MES.  
The restricted logistic regression model was then trained on an expanded data set of 275 
presentations with data available for the five restricted variables producing the following result. 
 
Full risk score for corticosteroid therapy failure:  
 
0.770800 – 0.2214970Mayo endoscopic subscore – 0.2039264Oral prednisone on admission 
–0.0090635Bowel frequency – 0.0003810CRP(mg/L) + 0.0120914Albumin(g/L)  
 
Validation and testing 
Leave-one-out cross validation was used. 
 
The full risk score for corticosteroid therapy failure score was applied to the data set of 275 
individuals with available data (Table 3.4). As with the partial risk score, increasing the threshold 
used to predict corticosteroid failure reduced the positive predictive value of the algorithm (Figure 
3.4).  
 
A threshold of 0.307 produced an 85% PPV for corticosteroid failure. This threshold decreased to 
0.161 and 0.0824 for 89% and 95% PPVs, respectively.  
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Table 3.4 Risk of corticosteroid therapy failure logistic regression model cut offs at discrete PPV 
intervals 
Threshold Sensitivity Specificity Accuracy PPV NPV % cases 
0.0824 0.125749 0.990741 0.465455 0.954545 0.422925 8 
0.161 0.281437 0.944444 0.541818 0.886792 0.459459 19 
0.307 0.526946 0.851852 0.654545 0.846154 0.538012 38 
 
PPV: positive predictive value; NPV: negative predictive value; % cases: the percent of the total 
number of cases below the corresponding threshold  
 
The 85%, 89% and 95% PPV thresholds encompassed 38%, 19% and 8% of the 275 presentations, 
respectively.  
 
Figure 3.4 PPV for corticosteroid failure at various thresholds of full risk of corticosteroid failure 
scores (n=275). PPV: positive predictive value. 
 
 
Alternative analytic approaches 
Bayesian networks and deep learning analyses were also trialled to derive a risk score. Neither of 
these approaches produced greater discriminatory powers than the stepwise logistic regression 
models. 
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Colectomy-by-discharge risk analysis 
A logistic regression model was also applied to the colectomy by 90 days clinical outcome. A 
meaningful risk score for colectomy by 90 days was not able to be derived from this admission data. 
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3.6 Discussion 
 
A continuous risk score for failure of corticosteroid therapy based on clinical, endoscopic and 
laboratory parameters available at the time of presentation was derived from 349 presentations of 
acute UC.   
 
This algorithm was derived from a large real-world cohort of patients treated at a single centre. As 
seen in other contemporaneous series, there was a predominance of male cases (54%). The fact that 
the study was performed at a large referral centre led to a skew towards corticosteroid treatment 
failure (60%). Those patients who presented directly to the referral centre had a corticosteroid 
failure rate of 50%. This figure is at the lower end the previously reported response range of 50-
70%.45  
 
This risk score is informative with regards to treatment failure and can provide an estimation of risk 
that is personalised to the patient and the severity of their immediate presentation. It is also versatile 
as it can be applied with or without the information obtained from an endoscopic assessment that, 
depending on the time and place of the presentation, may not always be available within 24 hours.  
 
With the additional data from the endoscopic assessment a larger proportion (38% versus 21%) of 
patients were able to be identified as being high (>85% PPV) risk for corticosteroid failure. The 
observed relationship between endoscopic severity and the failure of medical therapy has been well 
described elsewhere.6, 57, 63  
 
Whilst the UCEIS score has been found to have a better receiver operating characteristic (ROC) 
score for predicting the need for colectomy-by-discharge, the MES remains in widespread usage.64 
There is a balance to be struck between accessibility and the performance characteristics of the 
endoscopic scoring system. It was for these reasons and for consistency across the cohort that the 
MES was employed. 
 
Whilst this continuous risk score incorporates five clinical, laboratory and endoscopic parameters at 
a time, all are available from either the patient history or promptly available laboratory tests or 
endoscopy. As the algorithm is not a simple ‘rule’ based score, in the clinical setting it will be 
accessed via an online or application-based clinical calculator (Figure 3.5). Whilst this may seem a 
barrier to its application at the bedside, in the new era of personalised medicine clinicians are more 
accepting of computer-based algorithms accessed through clinical calculators.65 Another example in 
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gastroenterology of a score requiring calculation is the widely used MELD score. Like the MELD 
score, the risk of steroid failure score can be applied as an assessment of disease severity in acute 
UC at a given point in time that is linked to an important and informative clinical outcome. 
 
 
Figure 3.5 Example of an online clinical risk calculator result for an adapted partial (clinical) risk 
score showing a case at high risk of corticosteroid treatment failure 
 
Strengths of this study include prospective data collection, the size of the series and the number of 
parameters assessed. Compared to previously reported scores, only the abstract from Edinburgh that 
analysed 444 admissions generated by 323 patients used a larger total number of cases in its 
derivation cohort. Of these, detailed data was available for 97 admissions.  
 
The performance characteristics of this score compare favourably to those previously described to 
identify the likelihood of corticosteroid failure based on admission indices. The study of 49 patients 
from India identified just two variables that provided a PPV of 100% for corticosteroid failure.50 
However, the faecal calprotectin analysis was taken on a day three specimen so this algorithm is not 
purely based on presentation indices. 
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Whilst studies such as the recent abstract from Melbourne utilising admission faecal calprotectin are 
of interest, the practicality of using the faecal calprotectin to influence clinical management prior to 
day three of intravenous corticosteroid therapy requires either a reproducible and accurate bedside 
testing platform or a very prompt turnaround from a conventional laboratory based platform.  
 
Additionally, when considering the reproducibility of results from quantitative faecal assays, faecal 
collection and sample processing methods must be closely controlled to ensure uniformity. Even 
when these precautions are taken and the same testing platform is used, faecal calprotectin results 
can vary widely during the same day in the same patient with severe UC.66 As seen in previous 
chapters and the appendices of this thesis, in the experience of our centre this test performs poorly 
at separating moderate from severe levels of disease activity.  
 
Whilst other studies have sought to replicate easily applicable rule-based criteria such as that used 
in the Oxford index, this may be a simplistic approach. By applying the risk score a more 
personalised assessment of the risk of treatment failure is undertaken. The slight inconvenience of 
having to input the relevant data into a clinical calculator is outweighed by the informed and 
nuanced approach to individual patient care that is afforded by the tool. 
 
Shortcomings of the study include, single centre design. However, this does confer a degree of  
consistency in patient management and data collection. The series reflects a real world cohort of  
acute UC patients that has external validity to other analogous healthcare settings. Testing the 
newly derived score in a validation cohort will inform its performance characteristics in an 
independent series. 
 
The long duration of data collection spans a few eras of acute UC management. The series is 
uniquely placed to answer questions relating to corticosteroid therapy for biologic naïve patients. It 
spans the era of access to salvage medical therapy for all presentations. It also presents the findings 
from a series of patients free from maintenance biologics. In a similar way that immunomodulator 
therapy has been observed to alter severe UC outcomes, maintenance biologic therapy is likely to 
alter the natural history of the presentation, management and the likelihood of response to the 
offered treatment. 
 
Not all clinical indices evaluated in the univariate analysis were available for each patient. There 
were incomplete of data sets only for ESR (270/349), MES (275/349) and faecal calprotectin 
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(166/349) variables. This incompleteness of data could potentially lead to decreased 
representativeness of these variables in the univariate analysis.  
 
Both partial and full corticosteroid failure risk tools were trained on a dataset of 349 presentations 
of moderate-severe acute UC. The rate of intravenous corticosteroid failure was 60% in this cohort. 
The training of this algorithm was optimised for predicting treatment failure, and as a result the 
predictive characteristics for treatment success were affected (Figures 3.3 and 3.4). 
 
In more detail, the sensitivity and NPV calculations are affected by the fact that at the higher PPV 
and specificity thresholds there is a higher rate of false negative results. That is, there is a large 
number of patients whose risk scores lie above the threshold who go on to experience intravenous 
corticosteroid therapy failure. 
 
In a real-world situation, identifying those at the highest level of risk for intravenous corticosteroid 
treatment failure is the most clinically useful group to identify for possible early treatment 
escalation. As the default clinical pathway is to continue with at least three days of intravenous 
corticosteroid therapy, the application of this algorithm is unlikely to affect the treatment outcomes 
for those patients with falsely negative risk scores who present with indices reflecting lower disease 
burden and treatment refractoriness. 
 
Both the sensitivity and NPV can be altered by increasing the threshold value. However, this will 
result in the identification of a group with a more heterogenous risk profile for intravenous 
corticosteroid therapy failure. If these risk scores are to be implemented and subsequently evaluated 
for their ability to improve patient outcomes then clinicians would prefer the identification of a 
group at very high risk for corticosteroid therapy failure prior to changing currently accepted 
clinical practice. 
 
With regards to changing current clinical practice, this new risk score is able to inform the clinician 
as to the risk of corticosteroid therapy failure. The earlier institution of treatment escalation in the 
form of intensified medical therapy or surgery has been observed to confer improved medium and 
long term outcomes in severe UC patients.55 
 
In summary, a risk score based on a logistic model including the admission indices of oral 
corticosteroid failure, bowel frequency, CRP, albumin and either disease duration or MES was 
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trained on a set of 349 presentations of acute UC. This as yet unvalidated score has the potential to 
inform clinicians as to the timing of treatment escalation in acute UC. 
 
 
3.7 Future directions 
 
The next step for the developed risk scores are making them widely available for clinical use, 
initially on an internet-based platform.  
 
A randomised clinical trial utilising the risk scores as a basis for the implementation of early 
treatment escalation is currently in the early stages of development. 
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5.0 Appendices 
 
Appendix A 
A preliminary analysis of an n=270 cohort of patients for Chapter 1. This was a larger 
cohort of 270 presentations including 37 patients admitted with TWC moderate colitis and 
also those transferred from other facilities. This draft chapter includes the statistical 
approach undertaken in an attempt to obtain an expression that would accurately predict 
an ESR result based on a CRP and clinical variables at the time of presentation.  
As the root-mean-square deviation (RMSD) for the predicted ESR was 35.6mm/h it was 
determined to be of limited utility. Subsequently, the statistical approach detailed in the 
body of the thesis was pursued. 
 
Methods  
 
Study population 
During the study period 233 presentations with acute severe UC and 37 with moderately severe UC 
had paired ESR and CRP levels recorded within 24 hours of first presentation to hospital (Table 4). 
These presentations were generated by 252 individuals. There were no deaths of hospitalised 
patients as a consequence of UC, surgery or any subsequent complications.   
 
Statistics 
Spearman’s correlation was used to assess associations between raw ESR and CRP data. Robust 
regression with Huber weighting was used to assess the relationship between CRP and the ESR 
corrected for albumin, haemoglobin, gender and age. The residuals for the ESR values of the severe 
cases corrected for albumin and haemoglobin were correlated with the actual CRP values by 
Spearman’s correlation. 
 
The results of the robust regression were also used to determine a formula predicting an ESR 
corrected for albumin and haemoglobin. Leave-one-out cross validation was used to determine the 
robustness of this formula. Spearman’s correlation was used to correlate the relationship between 
the predicted and actual ESR value for the severe cases only.  
 
Root mean squared difference (RMSD) was used to determine the accuracy of the ESR prediction 
formula. 
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 Results 
 
There was a male predominance of 54% with a median age of 32 years at admission. Nineteen 
percent of cases were index (first) presentations of UC. The median time elapsed between UC 
diagnosis and admission was two years (IQR 1-8 years). Two thirds (67%) of cases had disease 
proximal to the splenic flexure. Less than one quarter (23%) of cases were receiving systemic 
immunosuppression at the time of presentation.  
 
Table 4. Moderately-acute severe UC patient characteristics 
 Presentations (n=270) 
Gender (male) 146 (54%) 
Median age at admission (range) 32 (15-86) 
Disease duration (median years) 2 (0-44) 
First UC presentation 
Relapse 
50 (19%) 
220 (81%) 
Presentation location 
Tertiary centre 
Other hospital 
 
190 (70%) 
80 (30%) 
Severity of episode by TWC 
Moderate 
Severe 
 
37 (14%) 
233 (86%) 
Disease extent (Montreal classification) 
Proctitis (E1)        
Left-sided (E2)    
Extensive (E3)      
 
2 (1%) 
87 (32%) 
181 (67%) 
Immunosuppression on admission  
None                 
Yes 
 
207 (77%) 
63 (23%) 
UC: ulcerative colitis; TWC: Truelove and Witts criteria 
 
Raw ESR and CRP data 
Both ESR and CRP on presentation were not normally distributed. The median (IQR) ESR was 
42mm/h (27-59mm/h). The median (IQR) CRP was 54mg/L (21-103mg/L). 
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ESR-CRP correlation, robust regression, predicted ESR formula  
Initial analyses revealed a weak correlation between the raw ESR and CRP (rho=0.38 by 
Spearman’s correlation).  The addition of 35 moderately severe cases modestly increased the 
strength of the correlation (rho=0.51 by Spearman’s correlation, robust regression t-statistic for 
ESR=8.49). The moderately severe cases were subsequently removed from further analysis in the 
ESR prediction calculations due to their tendency to reduce the correlative and predictive power of 
the series in these analyses. 
 
Correction by robust regression of the severely affected patient CRP against the ESR corrected for 
paired albumin and haemoglobin concentrations but not with the addition of either age or gender 
yielded significant t-statistics of 5.98, -4.73 and 5.00 for ESR, albumin and haemoglobin, 
respectively. The intercept/constant was 6.96.  
 
The Spearman’s correlation of the Huber weighted residuals from the CRP ~ ESR+Alb+Hb robust 
regression were correlated against CRP giving a rho=0.80. 
 
Formula cross-validation and performance appraisal 
Leave-one-out cross-validation produced an inter-quartile range for the intercept of 6.08-7.71. 
The intercept and beta coefficients for the significant variables were used to construct a formula 
initially solved for CRP. The formula was then solved for ESR to derive the equation:  
 
predicted ESR= (CRP + 3.37xalbumin - 1.04xhaemoglobin – 7)/1.08. 
 
The predicted ESR was plotted and correlated against the actual ESR giving a Spearman’s 
correlation of rho=0.67, R2=0.45. Therefore, following this model 45% of the variance of the CRP 
can be attributed to the paired combination of ESR corrected for albumin and haemoglobin results. 
 
The RMSD for the predicted ESR was 35.6mm/h. 
 
Determining and applying the CRP cut off for the n=270 cohort 
Compared to the traditional ESR cut off of >30mm/h, the lowest CRP value that produces a PPV of 
81% was ≥20mg/L. This threshold captures 88% of cases with an ESR >30mm/h. The area under 
the curve is 0.77. A cut off of 142mg/L was required to generate a PPV of 91% (Table 5); however 
this captured only 22% of cases. The PPV is consistently above 80% for CRP cut off values from 
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20-200mg/L (Figure 2). The level of accuracy was consistently between 77-78% for CRP cut off 
values from 10-20mg/L (Figure 3).   
 
Table 5. CRP cut off positive predictive values for a paired ESR of >30mm/h 
CRP cut off 
(≥mg/L) 
PPV  
(%) 
NPV 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
10 78 76 95 36 78 
20 81 65 88 51 77 
30 83 55 78 63 74 
142 91 34 22 95 43 
CRP: C-reactive protein; PPV: positive predictive value for CRP cut off having a matched ESR 
>30mm/h; NPV: negative predictive value for CRP cut off having a matched ESR >30mm/h  
 
 
  
Figure 2. Positive predictive value for a matched ESR >30mm/h for a paired CRP cutoff 
 
The application of the new CRP≥20mg/L cut off to the data altered the number of TWC fulfilled for 
61/270 (23%) of patients (Figure 3). Conversely, 209 or 77% of presentations remained unchanged 
in their number of TWC satisfied on admission.  
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Figure 3. CRP accuracy at varying CRP cut off values.  
 
  
Figure 4. Number of Truelove and Witts criteria present at admission by ESR and CRP criteria. 
There was a net increase in the number of TWC in 17 (6%) patients when the CRP≥20mg/L criteria 
was applied. Thirty-nine patients underwent an increase in their total number of severity criteria 
including eight having an upgraded diagnosis to severe from moderate colitis. Four of these 
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upgraded patients experienced corticosteroid therapy failure. In this group there were no 
colectomies performed prior to discharge.  
 
Overall, 22 patients underwent a decrease in their severity criteria with nine patients being 
downgraded from severe to moderate disease status. Five of this group experienced corticosteroid 
therapy failure. Two of the nine patients progressed to inpatient colectomy following an incomplete 
response to rescue therapy. 
 
Clinical outcomes 
Following the application of the CRP≥20mg/L cut off there were no statistically significant changes 
to the number of patients with corticosteroid therapy failure in either the moderate versus the severe 
group or in any single TWC allocation group (Figure 5).   
 
There were no statistically significant differences by Chi-squared or Fisher’s exact tests in 
colectomy-by-discharge rate by number of TWC satisfied on admission between the ESR>30 and 
CRP≥20 criteria (Figure 6).  
 
The number of colectomies prior to discharge in the moderate group did increase from two to four 
cases but this observation did not reach statistical significance. All four moderate cases that 
proceeded to colectomy-by-discharge satisfied at least one or more TWC. 
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Figure 5. Corticosteroid failure rate by number of TWC and inflammatory marker classification 
system 
 
 
Figure 6.  Colectomy-by-discharge rate by number of TWC fulfilled at admission and inflammatory 
marker allocation system 
 
 
Other markers of disease severity on admission to hospital 
 
Faecal calprotectin 
Faecal calprotectin results were available for 117 patients (Figure 5). The median calprotectin in the 
moderate colitis group was 2000μg/g (n=27, IQR 1300-3667μg/g) and 2000μg/g (n=23, IQR 1033-
3633μg/g) for ESR>30 and CRP≥20 criteria, respectively. For the severe colitis group the median 
calprotectin was 2100μg/g (n=90, IQR 937-4608μg/g) and 2100μg/g (n=94, IQR 1200-4608μg/g) 
for ESR>30 and CRP≥20 criteria respectively. There were no statistically significant differences 
between ESR>30 and CRP≥20 allocated moderate or severe groups. 
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Figure 7.  Faecal calprotectin at presentation by TWC activity on presentation and inflammatory 
marker allocation system. (12 data points not visualised due to y-axis limitation of 8000μg/g). 
 
Mayo endoscopic subscore 
Mayo endoscopic subscore results were available for 203 patients (Figure 8). There were no 
statistically significant differences found in MES results between ESR>30 and CRP≥20 allocated 
subgroups. There were also no significant differences found between groups allocated by the 
number of TWC satisfied on admission (TWC 0-1 and 4-5 groups combined).  
86 
 
 
 
Figure 8.  Mayo endoscopic subscore at presentation by TWC fulfilled and inflammatory marker 
allocation criteria 
 
Trial of cut off with the inclusion of immunosuppression data 
The results of the analyses performed in Chapter 2 reveal a trend towards a reduction in the 
presenting CRP level observed in patients on systemic immunosuppression. The cut off model was 
rerun with an adjustment of -14mg/L to the CRP concentration in those patients on systemic 
immunosuppression. 
 
The CRP cut off conferring an 81% PPV increased to of ≥23mg/L. There were minimal changes to 
other resultant parameters including the overall accuracy of the cut off threshold. 
 
The effect of disease extent on inflammatory markers in acute severe ulcerative colitis 
Mann-Whitney U-test analysis revealed no statistically significant correlation between disease 
distribution when the series was divided into extensive and left-sided disease (including proctitis) 
and either ESR or CRP level at presentation, p=0.29, p=0.59, respectively. Similarly, robust 
regression did not identify a statistically significant relationship between disease distribution and 
inflammatory marker levels.  
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Appendix B 
 
Abstract submitted to Digestive Disease Week 2018 and accepted for poster presentation 
 
MARKERS OF SYSTEMIC INFLAMMATION IN MODERATE-SEVERE ULCERATIVE COLITIS: 
WHAT LEVEL OF C-REACTIVE PROTEIN CONSTITUTES ACUTE SEVERE ULCERATIVE 
COLITIS? 
 
Background: The erythrocyte sedimentation rate (ESR) as a component of the Truelove and Witts 
Criteria (TWC) is the traditional inflammatory marker used for the assessment of ulcerative colitis 
(UC) activity. An ESR >30mm/hr is one of the four additional TWC that when present in addition to 
the mandatory stool frequency criteria, assigns the patient to the severe activity category. In some 
settings satisfying the TWC for severe disease is a requirement for the reimbursement of infliximab 
for use as rescue medical therapy following failure of intravenous corticosteroid therapy. 
 
 
 
In current clinical practice the C-reactive protein (CRP) is the most frequently assessed blood 
derived marker of systemic inflammation. 
 
 
 
Aim: To determine the equivalent CRP cut off for an ESR of >30mm/hr in patients with moderate-
severely active UC admitted for intravenous corticosteroid therapy. 
 
 
 
Methods: A retrospective analysis of prospectively collected data from 233 patients with TWC 
qualifying acute severe and 37 with moderately active UC admitted at a single tertiary referral 
centre was performed. Each patient had paired ESR and CRP assays performed in addition to the 
collection of other laboratory, clinical and endoscopic parameters. Statistical analyses were 
performed to determine a corresponding CRP cut off for acute severe UC on the basis of the 
positive predictive value and accuracy for having a paired ESR >30mm/hr. The entire series was 
allocated into groups by disease activity using the new CRP cut off in place of the ESR criteria. 
The characteristics of the allocation groups were compared using clinical outcome measures and 
an assessment of faecal calprotectin and Mayo endoscopic subscore (MES) at presentation. 
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Results: A CRP cut off of ≥20mg/L generated an 81% positive predictive value with a sensitivity of 
88% and an accuracy of 77% for having a paired ESR >30mm/hr. Using the CRP cut off in place of 
the ESR criteria eight patients were upgraded from moderate to severe UC. Four of these patients 
experienced steroid therapy failure. Nine patients were down staged from severe to moderately 
severe UC. Five of these patients experienced steroid therapy failure with two undergoing surgery 
during the admission. Disease activity allocation was unchanged in 94% of cases. There were no 
statistically significant differences between disease activity groups allocated by the traditional ESR 
versus the new CRP-based criteria in the presenting faecal calprotectin, MES or the clinical 
outcomes of intravenous corticosteroid failure or colectomy prior to discharge. 
 
 
 
Conclusion: The proposed CRP≥20mg/L cut off is an inclusive and sensitive cut off that when 
incorporated into the TWC, replacing the traditional ESR >30mm/hr criteria, had similar 
performance characteristics to the ESR criteria when used for the assessment of UC disease 
activity. 
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